Adicet Bio begins enrolling subjects in Phase I trial of autoimmune disease therapy [Yahoo! Finance]
Adicet Bio, Inc. (ACET)
Last adicet bio, inc. earnings: 5/3 05:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aceto.com/ir/index.html
Company Research
Source: Yahoo! Finance
Adicet Bio senior vice-president and chief medical officer Francesco Galimi said: “The favourable safety profile, cellular kinetics and B-cell depletion in peripheral blood and secondary lymphoid tissue demonstrated with ADI-001 clinical experience to date, positions ADI-001 to potentially bring a paradigm shift in the treatment of autoimmune diseases. “We expect to have several additional sites open for enrolment by the end of the fourth quarter of 2024, and further increase the number of active sites during the first quarter of 2025.” "Adicet Bio begins enrolling subjects in Phase I trial of autoimmune disease therapy" was originally created and published by Clinical Trials Arena , a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or com
Show less
Read more
Impact Snapshot
Event Time:
ACET
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACET alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACET alerts
High impacting Adicet Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ACET
News
- Adicet Bio, Inc. (NASDAQ: ACET) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma [Yahoo! Finance]Yahoo! Finance
- Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell CarcinomaBusiness Wire
- Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical OfficerBusiness Wire
ACET
Earnings
- 8/13/24 - Beat
ACET
Sec Filings
- 12/19/24 - Form 8-K
- 11/27/24 - Form 8-K
- 11/18/24 - Form 8-K
- ACET's page on the SEC website